These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 33645914)

  • 1. Impact of 6- versus 12-month dual antiplatelet therapy on clinical prognosis in patients with high bleeding risk: Insights from the 4-year results of the I LOVE IT 2 study.
    Zhang J; Qiu M; Na K; Ma S; Jiang Z; Li J; Li Y; Han Y
    Catheter Cardiovasc Interv; 2021 May; 97 Suppl 2():1025-1031. PubMed ID: 33645914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contribution of ESC DAPT guideline-endorsed high thrombotic risk features to long-term clinical outcomes among patients with and without high bleeding risk after PCI.
    Wang HY; Dou KF; Yin D; Zhang D; Gao RL; Yang YJ
    BMC Cardiovasc Disord; 2020 Jul; 20(1):313. PubMed ID: 32611318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Duration of Dual Antiplatelet Therapy for Patients at High Bleeding Risk Undergoing PCI.
    Valgimigli M; Cao D; Angiolillo DJ; Bangalore S; Bhatt DL; Ge J; Hermiller J; Makkar RR; Neumann FJ; Saito S; Picon H; Toelg R; Maksoud A; Chehab BM; Choi JW; Campo G; De la Torre Hernandez JM; Kunadian V; Sardella G; Thiele H; Varenne O; Vranckx P; Windecker S; Zhou Y; Krucoff MW; Ruster K; Zheng Y; Mehran R;
    J Am Coll Cardiol; 2021 Nov; 78(21):2060-2072. PubMed ID: 34794687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long versus short dual antiplatelet therapy in acute coronary syndrome patients treated with prasugrel or ticagrelor and coronary revascularization: Insights from the RENAMI registry.
    D'Ascenzo F; Bertaina M; Fioravanti F; Bongiovanni F; Raposeiras-Roubin S; Abu-Assi E; Kinnaird T; Ariza-Solé A; Manzano-Fernández S; Templin C; Velicki L; Xanthopoulou I; Cerrato E; Rognoni A; Boccuzzi G; Omedè P; Montabone A; Taha S; Durante A; Gili S; Magnani G; Autelli M; Grosso A; Blanco PF; Garay A; Quadri G; Varbella F; Queija BC; Paz RC; Fernández MC; Pousa IM; Gallo D; Morbiducci U; Dominguez-Rodriguez A; Valdés M; Cequier A; Alexopoulos D; Iñiguez-Romo A; Gaita F; Rinaldi M; Lüscher TF
    Eur J Prev Cardiol; 2020 May; 27(7):696-705. PubMed ID: 30862233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Duration of antiplatelet therapy after complex percutaneous coronary intervention in patients at high bleeding risk: a MASTER DAPT trial sub-analysis.
    Valgimigli M; Smits PC; Frigoli E; Bongiovanni D; Tijssen J; Hovasse T; Mafragi A; Ruifrok WT; Karageorgiev D; Aminian A; Garducci S; Merkely B; Routledge H; Ando K; Diaz Fernandez JF; Cuisset T; Nesa Malik FT; Halabi M; Belle L; Din J; Beygui F; Abhyankar A; Reczuch K; Pedrazzini G; Heg D; Vranckx P;
    Eur Heart J; 2022 Sep; 43(33):3100-3114. PubMed ID: 35580836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bleeding Risk, Dual Antiplatelet Therapy Cessation, and Adverse Events After Percutaneous Coronary Intervention: The PARIS Registry.
    Sorrentino S; Sartori S; Baber U; Claessen BE; Giustino G; Chandrasekhar J; Chandiramani R; Cohen DJ; Henry TD; Guedeney P; Ariti C; Dangas G; Gibson CM; Krucoff MW; Moliterno DJ; Colombo A; Vogel B; Chieffo A; Kini AS; Witzenbichler B; Weisz G; Steg PG; Pocock S; Urban P; Mehran R
    Circ Cardiovasc Interv; 2020 Apr; 13(4):e008226. PubMed ID: 32216472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ischemic/bleeding event after short dual-antiplatelet therapy in patients with high bleeding risk: Sub-analysis of the MODEL U-SES study.
    Hioki H; Kozuma K; Kinoshita Y; Nanasato M; Ito Y; Yamaguchi J; Shiode N; Hibi K; Tanabe K; Ako J; Morino Y; Hirohata A; Sonoda S; Nakagawa Y; Okada H; Nakagami T; Takamisawa I; Ando K; Abe M; Ikari Y
    J Cardiol; 2021 Aug; 78(2):107-113. PubMed ID: 33875313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short dual antiplatelet therapy in patients with high bleeding risk undergoing percutaneous coronary intervention: a systematic review and meta-analysis.
    Zhang J; Chen Z; Li C; Wang D; He S; Luo C; Luo F; He Y
    Coron Artery Dis; 2022 Nov; 33(7):580-589. PubMed ID: 36178984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual Antiplatelet Therapy Duration Based on Ischemic and Bleeding Risks After Coronary Stenting.
    Costa F; Van Klaveren D; Feres F; James S; Räber L; Pilgrim T; Hong MK; Kim HS; Colombo A; Steg PG; Bhatt DL; Stone GW; Windecker S; Steyerberg EW; Valgimigli M;
    J Am Coll Cardiol; 2019 Feb; 73(7):741-754. PubMed ID: 30784667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of long-term ticagrelor monotherapy following 1-month dual antiplatelet therapy in patients who underwent complex percutaneous coronary intervention: insights from the Global Leaders trial.
    Serruys PW; Takahashi K; Chichareon P; Kogame N; Tomaniak M; Modolo R; Chang CC; Komiyama H; Soliman O; Wykrzykowska JJ; de Winter RJ; Ferrario M; Dominici M; Buszman P; Bolognese L; Tumscitz C; Benit E; Stoll HP; Hamm C; Steg PG; Onuma Y; Jüni P; Windecker S; Vranckx P; Colombo A; Valgimigli M
    Eur Heart J; 2019 Aug; 40(31):2595-2604. PubMed ID: 31397487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of one-month versus twelve-month dual antiplatelet therapy after implantation of drug-eluting stents guided by either intravascular ultrasound or angiography in patients with acute coronary syndrome: rationale and design of prospective, multicenter, randomized, controlled IVUS-ACS and ULTIMATE-DAPT trial.
    Ge Z; Gao XF; Kan J; Kong XQ; Zuo GF; Ye F; Tian NL; Lin S; Liu ZZ; Shao YB; He YQ; Wen SY; Yang Q; Xia Y; Wang ZZ; Xiao PX; Li F; Zeng HS; Yang S; Wang Y; Tao L; Gao DS; Qu H; Qian XS; Han YL; Chen F; Zhang JJ; Chen SL
    Am Heart J; 2021 Jun; 236():49-58. PubMed ID: 33621541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clopidogrel Monotherapy After 1-Month DAPT in Patients With High Bleeding Risk or Complex PCI.
    Yamamoto K; Watanabe H; Morimoto T; Obayashi Y; Natsuaki M; Domei T; Yamaji K; Suwa S; Isawa T; Watanabe H; Yoshida R; Sakamoto H; Akao M; Hata Y; Morishima I; Tokuyama H; Yagi M; Suzuki H; Wakabayashi K; Suematsu N; Inada T; Tamura T; Okayama H; Abe M; Kawai K; Nakao K; Ando K; Tanabe K; Ikari Y; Morino Y; Kadota K; Furukawa Y; Nakagawa Y; Kimura T;
    JACC Asia; 2023 Feb; 3(1):31-46. PubMed ID: 36873770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of the Academic Research Consortium for High Bleeding Risk criteria in Chinese patients with atrial fibrillation and acute coronary syndrome or undergoing percutaneous coronary intervention.
    Lyu SQ; Zhu J; Wang J; Wu S; Zhang H; Shao XH; Yang YM
    Thromb Res; 2022 Jan; 209():16-22. PubMed ID: 34844044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Details on the effect of very short dual antiplatelet therapy after drug-eluting stent implantation in patients with high bleeding risk: insight from the STOPDAPT-2 trial.
    Watanabe H; Domei T; Morimoto T; Natsuaki M; Shiomi H; Toyota T; Ohya M; Suwa S; Takagi K; Nanasato M; Hata Y; Yagi M; Suematsu N; Yokomatsu T; Takamisawa I; Doi M; Noda T; Okayama H; Seino Y; Tada T; Sakamoto H; Hibi K; Abe M; Kawai K; Nakao K; Ando K; Tanabe K; Ikari Y; Hanaoka KI; Morino Y; Kozuma K; Kadota K; Furukawa Y; Nakagawa Y; Kimura T;
    Cardiovasc Interv Ther; 2021 Jan; 36(1):91-103. PubMed ID: 32086787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abbreviated or Standard Antiplatelet Therapy in HBR Patients: Final 15-Month Results of the MASTER-DAPT Trial.
    Landi A; Heg D; Frigoli E; Vranckx P; Windecker S; Siegrist P; Cayla G; Włodarczak A; Cook S; Gómez-Blázquez I; Feld Y; Seung-Jung P; Mates M; Lotan C; Gunasekaran S; Nanasato M; Das R; Kelbæk H; Teiger E; Escaned J; Ishibashi Y; Montalescot G; Matsuo H; Debeljacki D; Smits PC; Valgimigli M;
    JACC Cardiovasc Interv; 2023 Apr; 16(7):798-812. PubMed ID: 37045500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 3- or 1-Month DAPT in Patients at High Bleeding Risk Undergoing Everolimus-Eluting Stent Implantation.
    Mehran R; Cao D; Angiolillo DJ; Bangalore S; Bhatt DL; Ge J; Hermiller J; Makkar RR; Neumann FJ; Saito S; Picon H; Toelg R; Maksoud A; Chehab BM; De la Torre Hernandez JM; Kunadian V; Sardella G; Thiele H; Varenne O; Vranckx P; Windecker S; Zhou Y; Krucoff MW; Ruster K; Wang J; Valgimigli M;
    JACC Cardiovasc Interv; 2021 Sep; 14(17):1870-1883. PubMed ID: 34503737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abbreviated Antiplatelet Therapy After Coronary Stenting in Patients With Myocardial Infarction at High Bleeding Risk.
    Smits PC; Frigoli E; Vranckx P; Ozaki Y; Morice MC; Chevalier B; Onuma Y; Windecker S; Tonino PAL; Roffi M; Lesiak M; Mahfoud F; Bartunek J; Hildick-Smith D; Colombo A; Stankovic G; Iñiguez A; Schultz C; Kornowski R; Ong PJL; Alasnag M; Rodriguez AE; Paradies V; Kala P; Kedev S; Al Mafragi A; Dewilde W; Heg D; Valgimigli M;
    J Am Coll Cardiol; 2022 Sep; 80(13):1220-1237. PubMed ID: 36137672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS Registry.
    Chandrasekhar J; Bansilal S; Baber U; Sartori S; Aquino M; Farhan S; Vogel B; Faggioni M; Giustino G; Ariti C; Colombo A; Chieffo A; Kini A; Saporito R; Michael Gibson C; Witzenbichler B; Cohen D; Moliterno D; Stuckey T; Henry T; Pocock S; Dangas G; Gabriel Steg P; Mehran R
    Catheter Cardiovasc Interv; 2017 Jun; 89(7):E217-E225. PubMed ID: 27650638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High bleeding risk patients with acute coronary syndromes treated with contemporary drug-eluting stents and Clopidogrel or Ticagrelor: Insights from CHANGE DAPT.
    Zocca P; Kok MM; van der Heijden LC; van Houwelingen KG; Hartmann M; de Man FHAF; Stoel MG; Louwerenburg JHW; Knottnerus IL; Linssen GCM; Doggen CJM; von Birgelen C
    Int J Cardiol; 2018 Oct; 268():11-17. PubMed ID: 29801763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clopidogrel versus ticagrelor in high-bleeding risk patients presenting with acute coronary syndromes: insights from the multicenter START-ANTIPLATELET registry.
    Gragnano F; Moscarella E; Calabrò P; Cesaro A; Pafundi PC; Ielasi A; Patti G; Cavallari I; Antonucci E; Cirillo P; Pignatelli P; Palareti G; Pelliccia F; Gaudio C; Sasso FC; Pengo V; Gresele P; Marcucci R;
    Intern Emerg Med; 2021 Mar; 16(2):379-387. PubMed ID: 32557093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.